SCHEMBL4586321

SCHEMBL4586321

O=Cc1ccc2nccc(C(=O)O)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.57
CYP19A1 P11511 1/20 0.43
KDM4E B2RXH2 4/20 0.42
KDM4A O75164 3/20 0.41
RAB9A P51151 2/20 0.41
EGLN1 Q9GZT9 1/20 0.41
HIF1AN Q9NWT6 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM5A P29375 6/20 0.40
KDM5B Q9UGL1 5/20 0.40
KDM4C Q9H3R0 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 2/20 0.40
NPC1 O15118 2/20 0.40
POLB P06746 2/20 0.40
KMT2A Q03164 2/20 0.40
PSMD14 O00487 1/20 0.39
UNG P13051 1/20 0.39
EPRS1 P07814 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4586472 0.86 LMNA (0.56) LMNACYP19A1KDM4EKDM4ARAB9A
SCHEMBL22119781 0.83 LMNA (0.54) LMNAKDM4EKDM4ARAB9AKDM5A
SCHEMBL22119844 0.82 IP6K1 (0.53) LMNACYP19A1ALDH1A1MEN1KMT2A
SCHEMBL26965935 0.82 LMNA (0.49) LMNAKDM4EL3MBTL1KDM5AALDH1A1
SCHEMBL22119841 0.82 IP6K1 (0.53) LMNACYP19A1ALDH1A1MEN1KMT2A
SCHEMBL22189718 0.81 LMNA (0.51) LMNAKDM4CALDH1A1HPGD
SCHEMBL29581022 0.81 IP6K1 (0.52) LMNAKDM4EKDM5AKDM5BKDM4C
SCHEMBL28700824 0.81 IP6K1 (0.52) LMNAKDM4EKDM5AKDM5BKDM4C
SCHEMBL22189318 0.81 IP6K1 (0.52) LMNAKDM4EKDM5AKDM5BKDM4C
SCHEMBL22189716 0.81 LMNA (0.51) LMNAKDM4CALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214455-A1 Novel Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-09-04 US disclosed
EP-1879563-A4 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-07-16 EP disclosed
EP-1879563-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-01-23 EP disclosed
WO-2006132739-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214455-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 LMNA 1257/4885CYP19A1 4668/4885KDM4E 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.